| |
Rectal/Vaginal PrEP at HIVR4P Conference/South Africa Oct 28-31 2014
|
| |
| |
http://webcasts.hivr4p.org/yi/2014/28?link=nav&linkc=date
Preclinical Evaluation of TMC-278 LA, a Long-acting Formulation of Rilpivirine, Demonstrates Significant Protection from Vaginal HIV Infection
Olivia Snyder......http://webcasts.hivr4p.org/console/player/25019?mediaType=audio&
UNC Chapel Hill, Chapel Hill, NC, United States
HIV PrEP Dose Rationale for Cabotegravir (GSK1265744) Long-acting Injectable Nanosuspension
Bill Spreen.........http://webcasts.hivr4p.org/console/player/25020?mediaType=audio&
GlaxoSmithKline R&D, Research Triangle Park, NC, United States
ICAAC/2014: GSK Long-Acting ART Integrase inhibitor - Cabotegravir Injected Every 1, 2, or 3 Months Yields Adequate Troughs in Simulation - (09/09/14)
CROI/2014: Rectal & Vaginal PrEP - Long-Acting Integrase Inhibitor GSK744 for PrEP (Once Monthly or maybe longer)......http://www.natap.org/2014/CROI/croi_32.htm
"GSK744 LA has afforded high---level protection against repeated intrarectal SHIV challenges in rhesus macaques......plasma concentrations >3X PAIC90 result in 100% protection.....plasma levels corresponding to protection can be readily achieved in man with quarterly 800mg intramuscular injections.......These data support moving GSK744 LA into clinical evaluation as PrEP in high-risk men who have sex with men - Phase 2 safety and tolerability studies commence in Spring 2014....These data support the evaluation of GSK744 LA as PrEP in other challenge models - Low---dose intravaginal (40LB see link to this CROI webcast below) and high--dose intravaginal (941LB)"
Tenofovir Reservoir Intravaginal Rings Provide Superior Pharmacokinetics and Higher Sustained Drug Levels than Tenofovir Matrix Rings
Meredith Clark
CONRAD Eastern Virginia Medical School, Arlington, VA, United States
A Combination Vaginal Ring Releasing Dapivirine and Darunavir
Diarmaid Murphy.......http://webcasts.hivr4p.org/console/player/25022?mediaType=slideVideo&
Queen's University Belfast, Belfast, United Kingdom
Rectal Specific Gels Containing Maraviroc and/or Tenofovir Protect against Rectal SHIV Transmission in a Macaque Model
Walid Heneine........http://webcasts.hivr4p.org/console/player/25024?mediaType=slideVideo&
Centers for Disease Control and Prevention, Atlanta, GA, United States
http://webcasts.hivr4p.org/console/player/25022?mediaType=slideVideo&
|
|
| |
| |
|
|
|
